Clinical Trial Update: Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of trastuzumab and docetaxel in metastatic prostate cancer refractory to hormone therapy has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Prostate Cancer | Phase 2 | Status: COMPLETED